Today Ascertain, a revolutionary collaboration between Aegis Ventures and Northwell Holdings, announced a seed funding round to launch Optain, an artificial intelligence company that enables early identification and disease prevention through retinal imaging.

WANT was pleased to partner with Aegis Ventures and Northwell Holdings to create the Optain brand. Our partnership entailed crafting an impactful brand identity for Optain, one that resonates with its core values of excellence, compassion, and cutting-edge technology. From the inception of the brand name to the meticulous strategic framework, we collaborated closely to ensure Optain stands as a beacon of innovation in the eye healthcare space.

Optain is now at the foremost authority in AI-driven eye healthcare and is powered by the brand positioning: ‘See Beyond’.  By harnessing state-of-the-art algorithms and computer vision advancements, Optain empowers healthcare professionals to detect, diagnose, and treat eye conditions with unparalleled accuracy and efficiency. Together, we are ushering in a new era of proactive vision care that will positively impact lives worldwide.

With this $12 million investment, Optain is the first company launched by Ascertain, Aegis Ventures and Northwell Holdings’ collaboration to develop healthcare AI companies at scale. Ascertain (also named & branded by WANT) was created in April 2022 to combine leading medical, technology, data and business resources in a company creation platform that addresses healthcare’s most challenging quality, equity, and cost problems.